Dementia is associated with insulin resistance in patients with Parkinson's disease

Journal of the Neurological Sciences

Volumn 315, Issue 1-2, 2012, Pages 39-43

  Bosco, Domenico ^a   Plastino, Massimiliano ^a   Cristiano, Dario ^a   Colica, Carmela ^b   Ermio, Caterina ^c   De Bartolo, Matteo ^d   Mungari, Pasquale ^e   Fonte, Giulia ^f   Consoli, Domenico ^g   Consoli, Arturo ^f   Fava, Antonietta ^h  

^a S Giovanni di Dio Hospital   (Italy)

^b Council Research Center ^*  (Italy)

^c Lamezia Terme Hospital   (Italy)

^d Serv Neurophysiology   (Italy)

^e Crotone Hospital   (Italy)

^f CAREGGI UNIVERSITY HOSPITAL   (Italy)

^g G Jazzolino Hospital   (Italy)

^h UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

2 h OGTT; Dementia; Diabetes mellitus; Insulin Resistance; Parkinson Disease

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; LEVODOPA; LIPID; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; EDUCATIONAL STATUS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; ORAL GLUCOSE TOLERANCE TEST; PARKINSON DISEASE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DEMENTIA; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PARKINSON DISEASE; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84857992754     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.12.008     Document Type: Article

References (39)

1. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998; 339:1044-53. (Pubitemid 28457867)
2. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic study. J Am Med Assoc 1999;281:341-6. (Pubitemid 29061038)
3. Sveinbjörnsdottir S, Hicks AA, Jonsson T, Péturson H, Guǧmundsson G, Frigge ML, et al. Familial aggregation in Parkinson's disease in Iceland. N Engl J Med 2000;24: 1765-70.
4. Hatton N, Kobayashi H, Sasaki-Hatano Y, Sato K, Mizuno Y. Familial Parkinson's disease: a hint to elucidate the mechanisms of nigral degeneration. J Neurol 2003;250(Suppl. 3) III2-10.
5. Boulton AJ, Vinik AL, Arezzo JC, Bril V, Feldman EI, Freeman R, et al. Diabetic neuropathies: a statement by the Americ Diabetes Association. Diabetes Care 2005;28:956-62. (Pubitemid 40434506)
6. Tuomiletho J, Rastenyte D, Jousilahti P, Sarti C, Vartiainen E. Diabetes mellitus as a risk factor for death from stroke; prospective study of the middle-aged Finnish population. Stroke 1996;27:210-5. (Pubitemid 26044488)
7. Leibson CL, Rossa WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, et al. Risk of dementia among person with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997;145:301-8. (Pubitemid 27082028)
8. Powers KM, Smith-Weller T, Franklin GM, Longstreth Jr WT, Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord 2006;12:185-9.
9. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007;30:842-7. (Pubitemid 46562366)
10. Simon KC, Chen H, Schwarzschild MA, Ascherio A. Hypertension, hypercholesterolemia, diabetes and the risk of Parkinson disease. Neurology 2007;69:1688-95. (Pubitemid 350287125)
11. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
12. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical Diagnostic Criteria for Dementia Associated with Parkinson's disease. Mov Disord 2007;12 1689-07.
13. Roman GC, Tatemichi TK, Erkinjuntti T, Commings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60. (Pubitemid 23060253)
14. Montgomery AS, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9. (Pubitemid 9136500)
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
16. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent Development in Parkinson's Disease, 11. Florham Park, NJ: MacMillan; 1987. p. 153-63.
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
18. Genuth S, Alberti KG, Bennett P. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;52:833-7.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-9. (Pubitemid 15018832)
20. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. prevalence of Insulin Resistance in metabolic disorders: The Bruneck study. Diabetes 1998;47:1643-9. (Pubitemid 28445355)
21. Bosco D, Costa R, Plastino M, Cotronei P, Sperli T, Santacroce N, et al. Glucose metabolism in the idiopathic blepharoptosis: utility of the oral glucose tolerance test (OGTT) and of the insulin resistance index. J Neurol Sci 2009;284:24-8.
22. McKane WR, Stevens AB, Woods R, Andrews WJ, Henry RW, Bell PM. The assessment of hepatic and peripheral insulin sensitivity in hypertriglyceridemia. Metabolism 1990;12:1240-5.
23. Karhapaa P, Malkki M, Laakso M. Isolated low HDL cholesterol: an insulin resistance state. Diabetes 1994;43:411-7. (Pubitemid 24064248)
24. Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994;78:25-9. (Pubitemid 24026741)
25. Tong M, Dong M, De la Monte S. Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and Dementia with Lewy Bodies: potential role of manganese neurotoxicity. J Alzheimer Dis 2009;16(3):585-99.
26. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 2006;37:1184-8. (Pubitemid 43731859)
27. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Diabetes in Patients with idiopathic Parkinson's disease. Diabetes Care 2008;31:1808-12.
28. Weisskopf MG, Grodstein F, Ascherio A. Smoking and cognitive function in Parkinson's disease. Mov Disord 2007 Apr 15;22(5):660-5. (Pubitemid 46800135)
29. Ikeda K, Kashihara H, Tamura M, Kano O, Iwamoto K, Iwasaki Y. Body mass index and the risk of Parkinson disease. Neurology Jun 12 2006;68(24):2156-7.
30. Van Woert MH, Mueller PS. Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa. Clin Pharmacol Ther 1971;12:360-7.
31. Levy G, Tang MX, Lote LJ, Louis ED, Alfaro B, Mejia H, et al. Motor impairment in Parkinson's disease relationship in incident dementia and age. Neurology 2002; 55(4):539-44.
32. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006;21(8): 1123-38.
33. Stumvoll M, Goldstein BJ, Van Haeften TW. Type 2 diabetes; principles of pathogenesis and therapy. Lancet 2005;365:1333-46.
34. Chen H, Zhang SM, Schwarzschild MA, Herman MA, Willett WC, Ascherio A. Obesity and the risk of Parkinson's disease. Am J Epidemiol 2004;159:547-55. (Pubitemid 38327788)
35. Sirtori CR, Bolme P, Azarnoff DL. Metabolic responses to acute and chronic l-dopa administration in patients with parkinsonism. N Engl J Med 1972;287:729-33.
36. Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperlì T, et al. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 2010;288(1-2):112-6.
37. Bingham EM, Hopkins D, Smith D, Pernet A, Hallett W, Reed L. The role of insulin in human brain glucose metabolism: an 18-fluoro-deoxyglucose positron emission tomography study. Diabetes 2002;51:3384-90. (Pubitemid 35403440)
38. Blanchard JG, Duncan PM. Effect in combinations of insulin, glucose and scopolamine on radial arm maze performance. Pharmacol Biochem Behav 1997;58: 209-14. (Pubitemid 27334373)
39. Watson GS, Bernhardt T, Reger MA, Cholerton BA, Baker LD, Peskind ER. Insulin effects on CSF norepinephrine and cognition in Alzheimer disease. Neurobiol Aging 2006;27:38-41. (Pubitemid 41627948)